What do systematic reviews say?

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid probably leads to higher development of cataract at compared with intravitreal anti‐VEGF (moderate certainty).

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  Peto OR 7.49 [2.87, 19.6]
  Studies not reported
  Moderate

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

It is very uncertain whether summary of findings: intravitreal anti‐VEGF plus intravitreal steroid changes significant intraocular inflammation at compared with intravitreal anti‐VEGF (very low certainty).

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  Peto OR 0.53 [0.05, 5.08]
  Studies not reported
  Very low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid probably leads to higher raised intraocular pressure at compared with intravitreal anti‐VEGF (moderate certainty).

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  Peto OR 8.13 [4.67, 14.16]
  Studies not reported
  Moderate

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid showed no clear difference in systemic adverse events at compared with intravitreal anti‐VEGF (low certainty).

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  Peto OR 1.32 [0.61, 2.86]
  Studies not reported
  Low

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found